Download PDF
Neuropediatrics 2022; 53(03): 213-216
DOI: 10.1055/s-0042-1742305
Short Communication

A Case of ECHS1 Deficiency with Severe Encephalopathy and Status Epilepticus after a Propofol Sedation: Case Report

Matthias Preusse   *
1   Department of Pediatrics, Helios Medical Center, Witten-Herdecke University, Wuppertal, Germany
,
Georgia Paraschaki   *
2   Department of Pediatric Neurology, Helios Medical Center, Witten-Herdecke University, Wuppertal, Germany
,
Soeren Lutz
3   Department of Pediatric Neurology, Evangelisches Krankenhaus Oberhausen, Oberhausen, Germany
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Background Short-chain enoyl-CoA hydratase (ECHS1) deficiency is a rare metabolic disorder. Concerned patients present with Leigh syndrome symptoms or a Leigh-like syndrome. Only 58 patients are known worldwide. The ECHS1 is a key component in β-oxidation and valine catabolic pathways.

Case Here we report a 6-month-old Lebanese boy born to consanguineous parents. He presented an increased muscle tone, hyperexcitability, feeding problems, horizontal nystagmus, and developmental delay. Magnetic resonance imaging of the brain revealed frontal brain atrophy, corpus callosum atrophy, and T2 hyperintensity in pallidum, internal capsule, pons, and thalamus. In the postsedation phase, the patient displayed a sudden generalized seizure with transition to status epilepticus. Therefore, we conducted metabolic examinations, which showed elevated levels of 2-methyl-2,3-DiOH-butyrate and 3-methylglutaconate in urine. Single exome sequencing revealed the homozygous mutation c.476A > G in the ECHS1 gene.

Conclusion This case report describes the clinical symptoms and the diagnostics of ECHS1 deficiency. It shows the importance of further metabolic and genetic testing of patients with motoric conspicuities and developmental delay. It is important to be cautious with propofol sedation of patients who present an unknown neurological disorder, when metabolic disturbance or especially mitochondriopathy is suspected.

Keywords

ECHS1 - encephalopathy - neurodegeneration - case report

* Matthias Preusse and Georgia Paraschaki should be considered joint first author.




Publication History

Received: 27 June 2021

Accepted: 08 December 2021

Article published online:
28 January 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Peters H, Buck N, Wanders R. et al. ECHS1 mutations in Leigh disease: a new inborn error of metabolism affecting valine metabolism. Brain 2014; 137 (Pt 11): 2903-2908
    CrossrefPubMedGoogle Scholar
  • 2 Yamada K, Aiba K, Kitaura Y. et al. Clinical, biochemical and metabolic characterisation of a mild form of human short-chain enoyl-CoA hydratase deficiency: significance of increased N-acetyl-S-(2-carboxypropyl)cysteine excretion. J Med Genet 2015; 52 (10) 691-698
    CrossrefPubMedGoogle Scholar
  • 3 Sharpe AJ, McKenzie M. Mitochondrial fatty acid oxidation disorders associated with short-chain enoyl-CoA hydratase (ECHS1) deficiency. Cells 2018; 7 (06) E46
    CrossrefPubMedGoogle Scholar
  • 4 Burgin HJ, McKenzie M. Understanding the role of OXPHOS dysfunction in the pathogenesis of ECHS1 deficiency. FEBS Lett 2020; 594 (04) 590-610
    CrossrefPubMedGoogle Scholar
  • 5 Masnada S, Parazzini C, Bini P. et al. Phenotypic spectrum of short-chain enoyl-Coa hydratase-1 (ECHS1) deficiency. Eur J Paediatr Neurol 2020; 28: 151-158
    CrossrefPubMedGoogle Scholar
  • 6 Simon MT, Eftekharian SS, Ferdinandusse S. et al; Samoan Obesity, Lifestyle, and Genetic Adaptations (OLaGA) Study Group. ECHS1 disease in two unrelated families of Samoan descent: common variant - rare disorder. Am J Med Genet A 2021; 185 (01) 157-167
    CrossrefPubMedGoogle Scholar
  • 7 Ronchi D, Monfrini E, Bonato S. et al. Dystonia-ataxia syndrome with permanent torsional nystagmus caused by ECHS1 deficiency. Ann Clin Transl Neurol 2020; 7 (05) 839-845
    CrossrefPubMedGoogle Scholar
  • 8 Wu M, Gao W, Deng Z. et al. Two novel ECHS1 variants, affecting splicing and reducing enzyme activity, is associated with mitochondrial encephalopathy in infant: a case report. BMC Neurol 2020; 20 (01) 165
    CrossrefPubMedGoogle Scholar
  • 9 Yang H, Yu D. Clinical, biochemical and metabolic characterization of patients with short-chain enoyl-CoA hydratase(ECHS1) deficiency: two case reports and the review of the literature. BMC Pediatr 2020; 20 (01) 50
    CrossrefPubMedGoogle Scholar
  • 10 Sun D, Liu Z, Liu Y. et al. Novel ECHS1 mutations in Leigh syndrome identified by whole-exome sequencing in five Chinese families: case report. BMC Med Genet 2020; 21 (01) 149
    CrossrefPubMedGoogle Scholar
  • 11 Qin J, Li Y, Wang K. Propofol induces impairment of mitochondrial biogenesis through inhibiting the expression of peroxisome proliferator-activated receptor-γ coactivator-1α. J Cell Biochem 2019; 120 (10) 18288-18297
    CrossrefPubMedGoogle Scholar
  • 12 Meyer S, Kleinschmidt S. Diagnostische und therapeutische Prozeduren: Sedierung und Analgesie im Kindesalter. Monatsschr Kinderheilkd 2005; 153 (03) 291-303
    CrossrefPubMedGoogle Scholar
  • 13 Ganetzky R, Stojinski C. Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency. In: Adam MP, Ardinger HH, Pagon RA. et al., eds. GeneReviews®. Seattle: University of Washington; 2019
    Google Scholar
  • 14 Parikh S, Saneto R, Falk MJ. et al. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009; 11 (06) 414-430
    CrossrefPubMedGoogle Scholar
  • 15 Sato-Shirai I, Ogawa E, Arisaka A. et al. Valine-restricted diet for patients with ECHS1 deficiency: divergent clinical outcomes in two Japanese siblings. Brain Dev 2021; 43 (02) 308-313
    CrossrefPubMedGoogle Scholar